21 July 2017
The Medicines Patent Pool signed sublicences with new generic manufacturing partners Anhui Biochem United Pharmaceuticals from China, as well as Dr. Reddy’s Laboratories and Macleods Pharmaceuticals from India. The three companies have the rights to develop generic versions of ViiV Healthcare’s dolutegravir (DTG) and Gilead Sciences’ portfolio of six products. Dr. Reddy’s Laboratories also signed a licence to manufacture AbbVie’s lopinavir, ritonavir for Africa.
The foundation’s current partners Sun Pharma and Zheijang Huahai signed sublicensing agreements to produce DTG, while Natco was recently granted a sublicence for Gilead Sciences’ products. The MPP is now working with 20 sublicensing partners to produce World Health Organization-recommended and new HIV, hepatitis C and tuberculosis treatments.
Access our overview licence page
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.